Skip to main content

Representation of women in randomized clinical trials of cardiovascular disease prevention.

Publication ,  Journal Article
Melloni, C; Berger, JS; Wang, TY; Gunes, F; Stebbins, A; Pieper, KS; Dolor, RJ; Douglas, PS; Mark, DB; Newby, LK
Published in: Circ Cardiovasc Qual Outcomes
March 2010

BACKGROUND: The 2007 American Heart Association guidelines for cardiovascular disease prevention in women drew heavily on results from randomized clinical trials; however, representation of women in trials of cardiovascular disease prevention has not been systematically assessed. METHODS AND RESULTS: We abstracted 156 randomized clinical trials cited by the 2007 women's prevention guidelines to determine female representation over time and by clinical indication, prevention type, location of trial conduct, and funding source. Both women and men were represented in 135 of 156 (86.5%) trials; 20 trials enrolled only men; 1 enrolled only women. Among all trials, the proportion of women increased significantly over time, from 9% in 1970 to 41% in 2006. Considering only trials that enrolled both women and men, female enrollment was 18% in 1970 and increased to 34% in 2006. Female representation was higher in international versus United States-only trials (32.7% versus 26.7%) and primary versus secondary prevention trials (42.6% versus 26.6%). Female enrollment was comparable in government/foundation-funded versus industry-funded trials (31.9% versus 31.5%). Representation of women was highest among trials in hypertension (44%), diabetes (40%), and stroke (38%) and lowest for heart failure (29%), coronary artery disease (25%), and hyperlipidemia (28%). By contrast, women accounted for 53% of all individuals with hypertension, 50% with diabetes, 51% with heart failure, 49% with hyperlipidemia, and 46% with coronary artery disease. Sex-specific results were discussed in only 31% of primary trial publications. CONCLUSIONS: Enrollment of women in randomized clinical trials has increased over time but remains low relative to their overall representation in disease populations. Efforts are needed to reach a level of representation that is adequate to ensure evidence-based sex-specific recommendations.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Circ Cardiovasc Qual Outcomes

DOI

EISSN

1941-7705

Publication Date

March 2010

Volume

3

Issue

2

Start / End Page

135 / 142

Location

United States

Related Subject Headings

  • Women's Health Services
  • Women's Health
  • United States
  • Treatment Outcome
  • Time Factors
  • Sex Factors
  • Secondary Prevention
  • Research Support as Topic
  • Research Subjects
  • Randomized Controlled Trials as Topic
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Melloni, C., Berger, J. S., Wang, T. Y., Gunes, F., Stebbins, A., Pieper, K. S., … Newby, L. K. (2010). Representation of women in randomized clinical trials of cardiovascular disease prevention. Circ Cardiovasc Qual Outcomes, 3(2), 135–142. https://doi.org/10.1161/CIRCOUTCOMES.110.868307
Melloni, Chiara, Jeffrey S. Berger, Tracy Y. Wang, Funda Gunes, Amanda Stebbins, Karen S. Pieper, Rowena J. Dolor, Pamela S. Douglas, Daniel B. Mark, and L Kristin Newby. “Representation of women in randomized clinical trials of cardiovascular disease prevention.Circ Cardiovasc Qual Outcomes 3, no. 2 (March 2010): 135–42. https://doi.org/10.1161/CIRCOUTCOMES.110.868307.
Melloni C, Berger JS, Wang TY, Gunes F, Stebbins A, Pieper KS, et al. Representation of women in randomized clinical trials of cardiovascular disease prevention. Circ Cardiovasc Qual Outcomes. 2010 Mar;3(2):135–42.
Melloni, Chiara, et al. “Representation of women in randomized clinical trials of cardiovascular disease prevention.Circ Cardiovasc Qual Outcomes, vol. 3, no. 2, Mar. 2010, pp. 135–42. Pubmed, doi:10.1161/CIRCOUTCOMES.110.868307.
Melloni C, Berger JS, Wang TY, Gunes F, Stebbins A, Pieper KS, Dolor RJ, Douglas PS, Mark DB, Newby LK. Representation of women in randomized clinical trials of cardiovascular disease prevention. Circ Cardiovasc Qual Outcomes. 2010 Mar;3(2):135–142.

Published In

Circ Cardiovasc Qual Outcomes

DOI

EISSN

1941-7705

Publication Date

March 2010

Volume

3

Issue

2

Start / End Page

135 / 142

Location

United States

Related Subject Headings

  • Women's Health Services
  • Women's Health
  • United States
  • Treatment Outcome
  • Time Factors
  • Sex Factors
  • Secondary Prevention
  • Research Support as Topic
  • Research Subjects
  • Randomized Controlled Trials as Topic